BioXcel Therapeutics, Inc.(BTAI)

$0.07—Stale · unknown old

WatchlistAsk SA Chart

BioXcel Therapeutics, Inc.(BTAI)

NASDAQ • Last print unknown ago

$0.07—Stale · unknown old

WatchlistAsk SA Chart Studio

BTAI(BTAI)

BTAI

Next report

Nov 11 2026in 46 days

EPS estimate

($1.01)

Revenue estimate

$191394

EPS beats

6 of last 12

EPS surprise

Each report against the estimate that stood when it landed.

Nov 14 2023Aug 13 2026

Reported	EPS est	EPS actual	Surprise	Revenue est	Revenue actual	Surprise
Aug 13 2026	($0.44)	($0.49)	-11.4%	$484630	$182000	-62.4%
May 15 2026	($0.59)	($0.54)	+8.5%	$381491	$206000	-46.0%
Mar 26 2026	($0.34)	($0.58)	-70.6%	$151520	$256000	+69.0%
Nov 12 2025	($1.54)	($2.18)	-41.6%	$169020	$98000	-42.0%
Aug 12 2025	($2.30)	($2.45)	-6.5%	$257500	$120000	-53.4%
May 12 2025	($2.72)	($1.50)	+44.9%	$350000	$168000	-52.0%
Mar 27 2025	($4.36)	($3.57)	+18.1%	$718260	$366000	-49.0%
Nov 14 2024	($8.00)	($5.12)	+36.0%	$1M	$214000	-82.8%
Aug 6 2024	($12.16)	($3.36)	+72.4%	$930000	$1M	+18.7%
May 9 2024	($10.88)	($13.92)	-27.9%	$450000	$582000	+29.3%
Mar 12 2024	($15.68)	($12.16)	+22.4%	$710000	$376000	-47.0%
Nov 14 2023	($20.64)	($27.52)	-33.3%	$730000	$341000	-53.3%

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+2598.40%

EPS—

FY2028

Rev+204.69%

EPS—

FY2029

Rev+182.46%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$769,915	$21M	$63M	$179M	$399M
Low	$769,915	$21M	$63M	$179M	$399M
High	$769,915	$21M	$63M	$179M	$399M
EBITDA Avg	$-18M	$-10M	$7M	$11M	$47M
Low	$-18M	$-10M	$7M	$11M	$47M
High	$-18M	$-10M	$7M	$11M	$47M
EBIT Avg	$-18M	$-11M	$5M	$8M	$38M
Low	$-18M	$-11M	$5M	$8M	$38M
High	$-18M	$-11M	$5M	$8M	$38M
Net Income Avg	$-33M	$-26M	$-10M	$-8M	$18M
Low	$-33M	$-26M	$-10M	$-8M	$18M
High	$-33M	$-26M	$-10M	$-8M	$18M
EPS Avg	$-2.70	$-2.14	$-0.79	$-0.62	$1.48
Low	$-2.70	$-2.14	$-0.79	$-0.62	$1.48
High	$-2.70	$-2.14	$-0.79	$-0.62	$1.48
Analysts (Rev / EPS)	1 / 1	1 / 1	1 / 1	1 / 1	1 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$191,394	$190,521	$800,000	$1M	$2M	$2M
Low	$191,394	$190,521	$800,000	$1M	$2M	$2M
High	$191,394	$190,521	$800,000	$1M	$2M	$2M
EBITDA Avg	$-8M	$-4M	$519,062	$767,235	$1M	$1M
Low	$-8M	$-4M	$519,062	$767,235	$1M	$1M
High	$-8M	$-4M	$519,062	$767,235	$1M	$1M
EBIT Avg	$-8M	$-5M	$499,186	$743,346	$1M	$1M
Low	$-8M	$-5M	$499,186	$743,346	$1M	$1M
High	$-8M	$-5M	$499,186	$743,346	$1M	$1M
Net Income Avg	$-12M	$-9M	$-4M	$-4M	$-3M	$-3M
Low	$-12M	$-9M	$-4M	$-4M	$-3M	$-3M
High	$-12M	$-9M	$-4M	$-4M	$-3M	$-3M
EPS Avg	$-1.01	$-0.72	$-0.31	$-0.29	$-0.26	$-0.26
Low	$-1.01	$-0.72	$-0.31	$-0.29	$-0.26	$-0.26
High	$-1.01	$-0.72	$-0.31	$-0.29	$-0.26	$-0.26
Analysts (Rev / EPS)	1 / 1	1 / 1	1 / 1	1 / 1	1 / 1	1 / 1

Earnings Call Transcripts

No earnings transcripts available for BTAI

Transcripts may not be available for all companies

Explore More

52-Week Highs Breakout

Stocks breaking to new annual highs

52-Week Lows Oversold

S&P 500 oversold value screener

Trending Momentum

Relative strength momentum leaders

Earnings Calendar

Upcoming earnings dates & reports

S&P 500 Screener

Filter and sort all 500 stocks

Strategy Focus List

Continuous multi-factor scoring & catalyst forensics

Market Movers

Today's biggest gainers and losers